【24h】

COVID-19 Vaccine

机译:2019冠状病毒病疫苗

获取原文
       

摘要

A number of companies have announced the vaccines for COVID-19 pandemic that has caused extreme poverty, famine, and more than a billion people have lost livelihood all across the globe. Mass production of vaccine Sputnik V is underway at different locations to inoculate population in Russia, Philippines, Vietnam, Brazil, Saudi Arab, and United Arab Emirates (UAE), and India. mRNA based vaccine of Pfizer-BioNTech after passing phase 2 trial is ready for testing on thousands of volunteers. Oxford University-AstraZeneca vaccine is also under phase 3 trial in US, Brazil, and India. In September, Novavax Inc.’s vaccine will be ready for phase 3 trial. By early next year, two billions of doses will be ready of Novavax. Moderna Therapeutics conducting vaccine trial on 30 thousands volunteers, results will be known soon. Hundreds of thousand volunteers have registered already for vaccination in US and other parts of the world. SinoVac Biotech Ltd. has prepared a vaccine “CoronaVac” and inoculating volunteers in Indonesia and Brazil. CanSino Biologics Inc. in phase 2 trial on 508 volunteers found a satisfactory immune response to COVID-19 virus. Apart from vaccine preparation and availability, we provided data for therapy and treatment for COVID-19 and transmission and stability aspect of COVID-19 SARS-Cov-2 virus. The data and results presented in this article are very important and useful in containing, treating, and eliminating the pandemic COVID-19.
机译:许多公司已宣布为Covid-19大流行的疫苗引起了极端的贫困,饥荒,超过10亿人在全球各地失去了生计。疫苗痰v的大规模生产在不同地点进行,以在俄罗斯,菲律宾,越南,巴西,沙特阿拉伯和阿拉伯联合酋长国(阿联酋)和印度的不同地点。通过第2阶段试验后的辉瑞效果疫苗的mRNA疫苗已准备好测试成千上万的志愿者。牛津大学 - 阿斯塔尼卡疫苗也在美国,巴西和印度的第3阶段审判。 9月,Novavax Inc.的疫苗将准备第3阶段试验。在明年初,数十亿的剂量将是Novavax的准备。 Moderna治疗方法在30万志愿者上进行疫苗试验,结果很快就会着名。数十万志愿者已经注册了美国和世界其他地区的疫苗接种。 Sinovac Biotech有限公司在印度尼西亚和巴西接种了疫苗“冠心病”,并在印度尼西亚和巴西接种志愿者。 Cansino Biologics Inc.在508阶段试验中,志愿者发现对Covid-19病毒的令人满意的免疫反应。除疫苗准备和可用性外,我们还提供了Covid-19的治疗和治疗数据,以及Covid-19 SARS-COV-2病毒的传播和稳定方面。本文提出的数据和结果非常重要,可用于含有,治疗和消除大流行Covid-19。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号